Published in Endocrinology on March 24, 2004
The role of gut hormones in glucose homeostasis. J Clin Invest (2007) 3.36
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes (2010) 2.34
Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest (2004) 2.34
Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology (2010) 1.96
Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol (2008) 1.86
Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes (2013) 1.85
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes (2009) 1.62
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med (2010) 1.61
Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut (2008) 1.56
Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes (2008) 1.52
Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes (2010) 1.46
Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab (2008) 1.45
Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf) (2011) 1.43
Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation. Mol Cell Biol (2006) 1.42
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol (2007) 1.33
Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care (2009) 1.22
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab (2010) 1.22
Identification of small-molecule inducers of pancreatic beta-cell expansion. Proc Natl Acad Sci U S A (2009) 1.20
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest (2011) 1.20
MicroRNAs contribute to compensatory β cell expansion during pregnancy and obesity. J Clin Invest (2012) 1.17
Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes (2008) 1.15
Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta Pharmacol Sin (2009) 1.14
Akt and PTEN: beta-cell mass and pancreas plasticity. Trends Endocrinol Metab (2009) 1.13
Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. Proc Natl Acad Sci U S A (2007) 1.13
Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells. Naunyn Schmiedebergs Arch Pharmacol (2008) 1.10
Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells. Biomacromolecules (2009) 1.10
Alteration of peripheral blood lymphocyte subsets in acute pancreatitis. World J Gastroenterol (2006) 1.10
Hypoglycemia complicating bariatric surgery: incidence and mechanisms. Curr Opin Endocrinol Diabetes Obes (2011) 1.09
Vertical sleeve gastrectomy improves glucose and lipid metabolism and delays diabetes onset in UCD-T2DM rats. Endocrinology (2012) 1.09
The neurotransmitters glycine and GABA stimulate glucagon-like peptide-1 release from the GLUTag cell line. J Physiol (2005) 1.06
Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance. Endocrinol Metab (Seoul) (2014) 1.04
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One (2012) 1.01
Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 modulate beta-cell chromatin structure. J Biol Chem (2009) 1.01
GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene. J Lipid Res (2010) 0.99
Control of lipid metabolism by tachykinin in Drosophila. Cell Rep (2014) 0.97
RD Lawrence Lecture 2008: Targeting GLP-1 release as a potential strategy for the therapy of Type 2 diabetes. Diabet Med (2008) 0.97
Glucose sensing by gut endocrine cells and activation of the vagal afferent pathway is impaired in a rodent model of type 2 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol (2011) 0.95
Skp2 is required for incretin hormone-mediated β-cell proliferation. Mol Endocrinol (2011) 0.95
Dose combinations of exendin-4 and salmon calcitonin produce additive and synergistic reductions in food intake in nonhuman primates. Am J Physiol Regul Integr Comp Physiol (2010) 0.94
A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. J Control Release (2013) 0.93
Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats. Dis Model Mech (2012) 0.93
Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control. Proc Natl Acad Sci U S A (2013) 0.92
Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes (2010) 0.92
Evolution of type 2 diabetes mellitus in non morbid obese gastrectomized patients with Roux en-Y reconstruction: retrospective study. World J Surg (2010) 0.91
Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res (2011) 0.91
Pancreas-specific Gsalpha deficiency has divergent effects on pancreatic alpha- and beta-cell proliferation. J Endocrinol (2010) 0.91
Abnormal glucose tolerance testing following gastric bypass demonstrates reactive hypoglycemia. Surg Endosc (2010) 0.89
Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol (2013) 0.89
Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats. Eur J Histochem (2012) 0.88
Encapsulated cell grafts to treat cellular deficiencies and dysfunction. Crit Rev Biomed Eng (2011) 0.88
Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. Alzheimers Dement (2014) 0.88
Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb Blood Flow Metab (2012) 0.88
Can we protect the gut in critical illness? The role of growth factors and other novel approaches. Crit Care Clin (2010) 0.87
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud (2005) 0.86
The role of physical exercise in inflammatory bowel disease. Biomed Res Int (2014) 0.84
The role of the Wnt signaling pathway in incretin hormone production and function. Front Physiol (2012) 0.84
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab (2015) 0.84
Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARγ and histone acetylation. J Lipid Res (2011) 0.84
Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice. Am J Physiol Regul Integr Comp Physiol (2011) 0.83
The role of gastrointestinal hormones in hepatic lipid metabolism. Semin Liver Dis (2013) 0.83
JNK3 is required for the cytoprotective effect of exendin 4. J Diabetes Res (2014) 0.82
Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats. Peptides (2014) 0.82
The evolving place of incretin-based therapies in type 2 diabetes. Pediatr Nephrol (2010) 0.82
Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications. J Med Chem (2014) 0.81
Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (Part II): in silico prediction in antidiabetic extracts. PLoS One (2012) 0.81
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications. Diabetes Ther (2011) 0.81
GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One (2012) 0.81
Update on the protective molecular pathways improving pancreatic beta-cell dysfunction. Mediators Inflamm (2013) 0.81
Role of microRNAs in islet beta-cell compensation and failure during diabetes. J Diabetes Res (2014) 0.80
Functional characterization of N-terminally GFP-tagged GLP-1 receptor. J Biomed Biotechnol (2009) 0.80
Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab (2011) 0.80
Successful treatment of persistent hyperinsulinemic hypoglycemia with nifedipine in an adult patient. Endocr Pract (2010) 0.80
The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. Mol Neurobiol (2016) 0.80
Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Sci Rep (2015) 0.78
Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes (2009) 0.78
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions. Rev Diabet Stud (2007) 0.78
Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2010) 0.78
Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assays. PLoS One (2012) 0.78
Beta cell transplantation and immunosuppression: can't live with it, can't live without it. J Clin Invest (2007) 0.78
Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. J Endocrinol (2014) 0.77
Transcriptome analysis of food habit transition from carnivory to herbivory in a typical vertebrate herbivore, grass carp Ctenopharyngodon idella. BMC Genomics (2015) 0.77
G protein-coupled receptors as new therapeutic targets for type 2 diabetes. Diabetologia (2015) 0.77
Proteins and small molecules for cellular regenerative medicine. Physiol Rev (2013) 0.77
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes (2011) 0.77
Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf (2012) 0.76
Acting on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPER. Front Endocrinol (Lausanne) (2013) 0.76
Lixisenatide accelerates restoration of normoglycemia and improves human beta-cell function and survival in diabetic immunodeficient NOD-scid IL-2rg(null) RIP-DTR mice engrafted with human islets. Diabetes Metab Syndr Obes (2015) 0.76
Sitagliptin Treatment After Total Pancreatectomy With Islet Autotransplantation: A Randomized, Placebo-Controlled Study. Am J Transplant (2016) 0.76
Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. Exp Diabetes Res (2011) 0.75
Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetes. Saudi Med J (2014) 0.75
CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. Sci Rep (2017) 0.75
Genetic determinants predicting efficacy of glucose-lowering drugs?: a long way to go ... Diabetes Care (2010) 0.75
Role of intestinal peptides and the autonomic nervous system in postprandial hypotension in patients with multiple system atrophy. J Neurol (2012) 0.75
Maternal ileal interposition surgery confers metabolic improvements to offspring independent of effects on maternal body weight in UCD-T2DM rats. Obes Surg (2013) 0.75
Glucagon-like peptide 1 improves insulin resistance in vitro through anti-inflammation of macrophages. Braz J Med Biol Res (2016) 0.75
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. Clin Diabetes (2017) 0.75
Combined Oral Administration of GABA and DPP-4 Inhibitor Prevents Beta Cell Damage and Promotes Beta Cell Regeneration in Mice. Front Pharmacol (2017) 0.75
Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells. PLoS One (2017) 0.75
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med (1996) 2.94
Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A (1987) 2.79
Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes (2000) 2.50
Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia (2010) 2.40
Chemical characterization of leptin-activated neurons in the rat brain. J Comp Neurol (2000) 2.21
Predicting cardiac complications in patients undergoing non-cardiac surgery. J Gen Intern Med (1986) 2.13
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A (2000) 1.91
Inactivation of the winged helix transcription factor HNF3alpha affects glucose homeostasis and islet glucagon gene expression in vivo. Genes Dev (1999) 1.86
Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology (1999) 1.79
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes (2004) 1.68
Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. Endocrinology (2000) 1.63
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia (2009) 1.58
Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol (1997) 1.43
Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor -/- mice. Endocrinology (1998) 1.40
Alpha-cell-specific expression of the glucagon gene is conferred to the glucagon promoter element by the interactions of DNA-binding proteins. Mol Cell Biol (1988) 1.35
The LIM domain homeobox gene isl-1 is a positive regulator of islet cell-specific proglucagon gene transcription. J Biol Chem (1995) 1.32
Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology (2000) 1.31
Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology (1994) 1.30
Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice. Diabetes (1998) 1.28
Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia (2010) 1.28
Regulation of glucagon-like peptide-1 synthesis and secretion in the GLUTag enteroendocrine cell line. Endocrinology (1998) 1.24
Characterization and functional role of voltage gated cation conductances in the glucagon-like peptide-1 secreting GLUTag cell line. J Physiol (2004) 1.23
Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A (1999) 1.22
Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des (2006) 1.21
Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol (1997) 1.20
Identification and characterization of a novel sucrose-non-fermenting protein kinase/AMP-activated protein kinase-related protein kinase, SNARK. Biochem J (2001) 1.13
Activation of proglucagon gene transcription through a novel promoter element by the caudal-related homeodomain protein cdx-2/3. Mol Cell Biol (1996) 1.10
Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels (2002) 1.09
Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology (2000) 1.08
UVB radiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints. Oncogene (1996) 1.07
Glucagon gene 5'-flanking sequences direct expression of simian virus 40 large T antigen to the intestine, producing carcinoma of the large bowel in transgenic mice. J Biol Chem (1992) 1.06
Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes (1998) 1.06
Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling. Diabetes (1998) 1.05
Proglucagon processing in a rat islet cell line resembles phenotype of intestine rather than pancreas. Endocrinology (1986) 1.04
Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem (2001) 1.03
Immunocytochemical localization of parathyroid hormone-like peptide in the rat fetus. Cancer Res (1991) 1.02
Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology (1997) 1.00
Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol (1997) 1.00
Parathyroid hormone-related peptide expression in primary and metastatic liver tumours. Histopathology (1993) 0.99
The Cushing syndrome induced by medroxyprogesterone acetate. Ann Intern Med (1989) 0.98
Essential requirement for Pax6 in control of enteroendocrine proglucagon gene transcription. Mol Endocrinol (1999) 0.98
Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol (1999) 0.98
Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch (2001) 0.96
Cell-specific post-translational processing of preproglucagon expressed from a metallothionein-glucagon fusion gene. J Biol Chem (1986) 0.96
Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes (1999) 0.96
Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem (1997) 0.94
Islet cell and extrapancreatic expression of the LIM domain homeobox gene isl-1. Mol Endocrinol (1991) 0.94
Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem (1999) 0.93
Glucagon gene transcription in an islet cell line is regulated via a protein kinase C-activated pathway. J Biol Chem (1987) 0.93
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res (2001) 0.93
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol (2000) 0.93
Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. J Clin Endocrinol Metab (1990) 0.93
UVB radiation-activated genes induced by transcriptional and posttranscriptional mechanisms in rat keratinocytes. Am J Physiol (1995) 0.90
The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem (2000) 0.90
Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab (2000) 0.89
Activation of amylin gene transcription by LIM domain homeobox gene isl-1. Mol Endocrinol (1996) 0.87
Transcriptional regulation of genes encoding insulin, glucagon, and angiotensinogen by sodium butyrate in a rat islet cell line. Mol Cell Biol (1987) 0.87
Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. Am J Physiol (1997) 0.87
Inhibition of pancreatic proglucagon gene expression in mice bearing subcutaneous endocrine tumors. Am J Physiol (1994) 0.87
The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol (2004) 0.86
Identification of domains mediating transcriptional activation and cytoplasmic export in the caudal homeobox protein Cdx-3. J Biol Chem (1999) 0.86
Reactive human bile ductules express parathyroid hormone-related peptide. Histopathology (1993) 0.86
Glucagon response to hypoglycemia is improved by insulin-independent restoration of normoglycemia in diabetic rats. Endocrinology (1996) 0.85
Alterations in proglucagon processing and inhibition of proglucagon gene expression in transgenic mice which contain a chimeric proglucagon-SV40 T antigen gene. J Biol Chem (1992) 0.85
The caudal homeobox protein cdx-2/3 activates endogenous proglucagon gene expression in InR1-G9 islet cells. Mol Endocrinol (1997) 0.85
Parathyroid hormone-related peptide is a downstream target for ras and src activation. J Biol Chem (1994) 0.84
New frontiers in the biology of GLP-2. Regul Pept (2000) 0.83
Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action. Diabetes (2000) 0.83
Ultraviolet radiation induction of ornithine decarboxylase in rat keratinocytes. Cancer Res (1990) 0.83
Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology (2004) 0.83
Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology (2000) 0.83
Proglucagon gene expression is induced by gastrin-releasing peptide in a mouse enteroendocrine cell line. Endocrinology (1996) 0.82
Parathyroid hormone-like peptide shares features with members of the early response gene family: rapid induction by serum, growth factors, and cycloheximide. Cancer Res (1992) 0.82
Expression of peptide hormone genes in human islet cell tumors. Diabetes (1988) 0.81
Differential expression of RNA transcripts encoding unique carboxy-terminal sequences of human parathyroid hormone-related peptide. Mol Endocrinol (1994) 0.81
Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem (2000) 0.81
Divergent regulation of human and rat proglucagon gene promoters in vivo. Am J Physiol (1999) 0.81
Regulation of parathyroid hormone-related peptide (PTHrP) gene transcription: cell- and tissue-specific promoter utilization mediated by multiple positive and negative cis-acting DNA elements. Mol Endocrinol (1992) 0.80
The LIM domain homeobox gene isl-1: conservation of human, hamster, and rat complementary deoxyribonucleic acid sequences and expression in cell types of nonneuroendocrine lineage. Endocrinology (1994) 0.79
The proglucagon gene upstream enhancer contains positive and negative domains important for tissue-specific proglucagon gene transcription. Mol Endocrinol (1995) 0.79
Developmental and tissue-specific regulation of proglucagon gene expression. Endocrinology (1990) 0.78
Leptin sensitivity in nonobese glucagon-like peptide I receptor -/- mice. Diabetes (1997) 0.78
Parathyroid hormone-like peptide in normal and neoplastic mesothelial cells. Cancer (1990) 0.78
Interaction of TPA and ultraviolet B radiation in regulation of ODC gene expression in rat keratinocytes. Am J Physiol (1992) 0.78
Glucagon gene 3'-flanking sequences direct formation of proglucagon messenger RNA 3'-ends in islet and nonislet cells lines. Mol Endocrinol (1990) 0.77
Cardiovascular surgery in the hypothyroid patient. Arch Intern Med (1985) 0.77
Structural determinants for activity of glucagon-like peptide-2. Biochemistry (2000) 0.77
Rapid induction of parathyroid hormone-like peptide gene expression by sodium butyrate in a rat islet cell line. Mol Endocrinol (1991) 0.77
Multiple cis-acting domains mediate basal and adenosine 3',5'-monophosphate-dependent glucagon gene transcription in a mouse neuroendocrine cell line. Endocrinology (1993) 0.77
Synthesis, secretion and biological actions of the glucagon-like peptides. Pediatr Diabetes (2000) 0.77
Synthesis and secretion of somatostatin-28 and -14 by fetal rat intestinal cells in culture. Am J Physiol (1990) 0.77
Regulation of peptide-YY synthesis and secretion in fetal rat intestinal cultures. Endocrinology (1991) 0.77
Tissue-specific differences in the levels of proglucagon-derived peptides in streptozotocin-induced diabetes. Endocrinology (1989) 0.77
Growth factor-like properties of parathyroid hormone-related peptide in transfected rodent cell line. Cancer Res (1993) 0.77
Development of colonic and pancreatic endocrine tumours in mice expressing a glucagon-SV40 T antigen transgene. Virchows Arch (1996) 0.76
Ultraviolet B radiation induction of ornithine decarboxylase gene expression in mouse epidermis. Biochem J (1990) 0.76
Smoking habits in hospital. Can Med Assoc J (1982) 0.75
Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor. J Physiol (2012) 0.75
Pseudotumour cerebri in association with polyarthritis, urticaria and cryoglobulinemia. Can Med Assoc J (1985) 0.75
Region- and age-specific differences in proglucagon gene expression in the central nervous system of wild-type and glucagon-simian virus-40 T-antigen transgenic mice. Endocrinology (1993) 0.75